JMIR Public Health and Surveillance (Oct 2023)

Immune-Boosting Effect of the COVID-19 Vaccine: Real-World Bidirectional Cohort Study

  • Ming Liu,
  • Tianshuo Zhao,
  • Qiuyue Mu,
  • Ruizhi Zhang,
  • Chunting Liu,
  • Fei Xu,
  • Luxiang Liang,
  • Linglu Zhao,
  • Suye Zhao,
  • Xianming Cai,
  • Mingting Wang,
  • Ninghua Huang,
  • Tian Feng,
  • Shiguang Lei,
  • Guanghong Yang,
  • Fuqiang Cui

DOI
https://doi.org/10.2196/47272
Journal volume & issue
Vol. 9
p. e47272

Abstract

Read online

BackgroundAs the SARS-CoV-2 attenuates and antibodies from the COVID-19 vaccine decline, long-term attention should be paid to the durability of primary booster administration and the preventive effect of the second or multiple booster doses of the COVID-19 vaccine. ObjectiveThis study aimed to explore the durability of primary booster administration and the preventive effect of second or multiple booster doses of the COVID-19 vaccine. MethodsWe established a bidirectional cohort in Guizhou Province, China. Eligible participants who had received the primary booster dose were enrolled for blood sample collection and administration of the second booster dose. A retrospective cohort for the time of administration was constructed to evaluate antibody attenuation 6-12 months after the primary booster dose, while a prospective cohort on the vaccine effect of the second booster dose was constructed for 4 months after the second administration. ResultsBetween September 21, 2022, and January 30, 2023, a total of 327 participants were included in the final statistical analysis plan. The retrospective cohort revealed that approximately 6-12 months after receiving the primary booster, immunoglobulin G (IgG) slowly declined with time, while immunoglobulin A (IgA) remained almost constant. The prospective cohort showed that 28 days after receiving the second booster, the antibody levels were significantly improved. Higher levels of IgG and IgA were associated with better protection against COVID-19 infection for vaccine recipients. Regarding the protection of antibody levels against post–COVID-19 symptoms, the increase of the IgG had a protective effect on brain fog and sleep quality, while IgA had a protective effect on shortness of breath, brain fog, impaired coordination, and physical pain. ConclusionsThe IgG and IgA produced by the second booster dose of COVID-19 vaccines can protect against SARS-CoV-2 infection and may alleviate some post–COVID-19 symptoms. Further data and studies on secondary booster administration are required to confirm these conclusions.